Plasmodium falciparum genetic factors rather than host factors are likely to drive resistance to ACT in Ghana

Artemisinin-based combination therapy (ACT) partner drugs, currently used in Ghana are lumefantrine, amodiaquine and piperaquine. Plasmodium falciparum isolates with reduced susceptibility to these partner drugs ...

Source: Malaria Journal - July 15, 2020 Category: Infectious Diseases Authors: Peter Hodoameda, Nancy Odurowah Duah-Quashie, Charles Oheneba Hagan, Sena Matrevi, Benjamin Abuaku, Kwadwo Koram and Neils Ben Quashie Tags: Research Source Type: research